Diagnostics

Avant Technologies, Inc. (OTCQB: AVAI) (“Avant” or the “Company”), announces that it has entered into a non-binding letter of intent (“LOI”) for a potential business combination with Ainnova Tech, Inc. (Ainnova). Ainnova, the Company’s joint venture partner, is a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI). Ainnova’s technology […]

Cancer diagnostic firm Caris Life Sciences said on Monday it is targeting a valuation of up to $5.3 billion in its U.S. initial public offering, as the market for new listings rebounds. Irving, Texas-based Caris, backed by investment firm Sixth Street, is seeking up to $423.5 million by offering 23.5 million shares priced between $16

23andMe has a path to a higher purchase price than the $256 million offered by biotech giant Regeneron after the genetic-testing company’s former chief executive pushed a bankruptcy court to reopen its sale process. 23andMe was set to sell itself in bankruptcy to Regeneron before former CEO Anne Wojcicki bid $305 million after the auction